83 related articles for article (PubMed ID: 24121456)
1. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer.
Nakai Y; Isayama H; Sasaki T; Takahara N; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Yamamoto K; Mohri D; Kogure H; Yamamoto N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1291-7. PubMed ID: 24121456
[TBL] [Abstract][Full Text] [Related]
2. CA19-9 serum concentrations--analysis of the serum kinetics during first-line therapy of pancreatic cancer in relation to overall survival.
Klapdor R; Bahlo M; Babinski A; Klapdor S
Anticancer Res; 2010 May; 30(5):1869-74. PubMed ID: 20592394
[TBL] [Abstract][Full Text] [Related]
3. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
4. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer.
Usón Junior PLS; Callegaro-Filho D; Bugano DDG; Moura F; Maluf FC
J Gastrointest Cancer; 2018 Dec; 49(4):481-486. PubMed ID: 28924968
[TBL] [Abstract][Full Text] [Related]
7. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
Boeck S; Haas M; Laubender RP; Kullmann F; Klose C; Bruns CJ; Wilkowski R; Stieber P; Holdenrieder S; Buchner H; Mansmann U; Heinemann V
Clin Cancer Res; 2010 Feb; 16(3):986-94. PubMed ID: 20103662
[TBL] [Abstract][Full Text] [Related]
8. [Value of combined therapy in pancreatic cancer with a poor prognosis: analysis of 233 clinical cases].
Wang Y; Zhao P; Wang CF; Shan Y; Zhao DB; Tian YT; Sun YM; Che X; Zhang JW
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2381-5. PubMed ID: 20137689
[TBL] [Abstract][Full Text] [Related]
9. Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
Kim ST; Lee J; Sun JM; Park YH; Ahn JS; Park K; Ahn MJ
Oncology; 2010; 79(1-2):78-84. PubMed ID: 21071994
[TBL] [Abstract][Full Text] [Related]
10. Performance status is an important prognostic factor in second line treatment of pancreaticobiliary adenocarcinoma.
Erdogan B; Turkmen E; Uzunoglu S; Tanriverdi O; Cicin I
Hepatogastroenterology; 2013 Sep; 60(126):1479-83. PubMed ID: 23933941
[TBL] [Abstract][Full Text] [Related]
11. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
12. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer.
Chadha AS; Kocak-Uzel E; Das P; Minsky BD; Delclos ME; Mahmood U; Guha S; Ahmad M; Varadhachary GR; Javle M; Katz MH; Fleming JB; Wolff RA; Crane CH; Krishnan S
Acta Oncol; 2015 Jul; 54(7):971-8. PubMed ID: 25608822
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):985-90. PubMed ID: 23995699
[TBL] [Abstract][Full Text] [Related]
14. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
[TBL] [Abstract][Full Text] [Related]
15. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer.
Chen Y; Shao Z; Chen W; Xie H; Wu Z; Qin G; Zhao N
Oncotarget; 2017 May; 8(18):29925-29934. PubMed ID: 28404893
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
17. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
[TBL] [Abstract][Full Text] [Related]
18. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
Yang ZJ; Wei RJ; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
[TBL] [Abstract][Full Text] [Related]
20. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Lorch A; Bascoul-Mollevi C; Kramar A; Einhorn L; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin K; Lotz JP; Germà-Lluch JR; Powles T; Kollmannsberger C; Beyer J
J Clin Oncol; 2011 Jun; 29(16):2178-84. PubMed ID: 21444870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
